Pancreatic Pseudocysts Treatment & Management
- Author: Louis R Lambiase, MD, MHA; Chief Editor: BS Anand, MD more...
The goal of therapy is avoidance of complications. Note the following:
About 10% of pseudocysts become infected.
Pseudocysts can also rupture. A controlled rupture into an enteric organ can sometimes cause GI bleeding. A free rupture into the peritoneal cavity produces abdominal pain and, rarely, peritonitis or even death.
Most pseudocysts resolve without interference and only require supportive care.
Several studies have indicated that the size of the cyst and the length of time the cyst has been present are poor predictors of complications. In general, larger cysts are more likely to become symptomatic or cause complications. However, some patients with larger collections do well; therefore, the size of the pseudocyst alone is not an indication for drainage.
Indications for drainage include the following:
Concern about possible malignancy
Management of pseudocysts requires a team approach. Gastroenterologists, surgeons, and invasive radiologists must work together to determine the necessity, timing, and method of intervention. If nonsurgical drainage is contemplated, it is important to elucidate the anatomy of the pancreatic duct beforehand. This may be done via endoscopic retrograde cholangiopancreatography (ERCP) or magnetic resonance imaging (MRI). A large number of patients who fail or have complications with nonsurgical drainage have disruption or stenosis of the pancreatic duct.
Diet and activity
Patients may eat a low-fat diet as tolerated. Patients in whom eating causes abdominal pain need parenteral or enteral nutrition through a percutaneously or endoscopically placed jejunal tube.
Patients may engage in activities as tolerated.
Patients who have endoscopically placed stents must be monitored via serial computed tomography (CT) scans to observe resolution of the cyst. Stents may then be endoscopically removed after resolution.
Closely monitor patients with percutaneous drains for pain, infection, or catheter migration. Remove the drain when drainage ceases.
Drainage options are outlined below.
Percutaneous aspiration is useful only to establish a diagnosis or as a temporizing measure. It has a 54% failure rate and a 63% recurrence rate. This technique has a relatively high risk of infecting the pseudocyst. Percutaneous drainage may have a higher complication rate and inpatient mortality rate than surgical drainage.
Percutaneous catheter drainage is the procedure of choice for treating infected pseudocysts, allowing for rapid drainage of the cyst and identification of any microbial organism. A high recurrence and failure rate exist, but catheter drainage may be a good temporizing measure.
Percutaneous catheter drainage is contraindicated in patients who are poorly compliant and cannot manage a catheter at home. It is also contraindicated in patients with strictures of the main pancreatic duct and in patients with cysts containing bloody or solid material.
Endoscopic drainage may be either transpapillary (via endoscopic retrograde cholangiopancreatography [ERCP]) or transmural. Both modalities require careful patient selection to ensure success and safety.
Transpapillary drainage, while safer and more effective than transmural drainage, requires cyst communication with the pancreatic duct. This technique may be technically challenging because it requires wire passage and stenting through the pancreatic duct to the pseudocyst. The success rate is about 80%. The recurrence rate is 10-14%, and, in most series, the complication rate (mainly pancreatitis) is approximately 13%. See the image below.
Endoscopic transmural drainage is also possible. This involves performing an endoscopy and finding a bulge within the wall of the stomach or duodenum caused by compression of the pseudocyst. The cyst is generally entered using a needle knife to cut through the gastric or duodenum wall, and a series of pigtail stents are placed through the resulting communication. Some have adapted the technique to avoid diathermy, thus decreasing possible complications. The method has an 82-89% success rate in very experienced hands. The recurrent rate is 6-18%. The complication rate is 20%, with the most feared complication being bleeding.
One report suggested that the complication rate decreases and efficacy increases with experience. Weckman reported an approximately 86% success rate with endoscopic drainage with a 10% complication rate and a 14% failure rate. There appeared to be about a 15% recurrence rate. There was no real difference in outcome in patients treated with a transpapillary or transmural approach.
In December 2013, the FDA approved marketing of the AXIOS Stent and Delivery System for the treatment of pancreatic pseudocysts. Approval of the stent, which creates a new temporary opening between the pancreas and the gastrointestinal tract, was based on a study of 33 patients with pancreatic pseudocysts at least 6 cm in diameter. In this study, stents were successfully placed 90.9% of the time, 97% of the successfully implanted stents stayed in place for the duration of treatment, 93% of the stents remained open to allow drainage for the duration of treatment, and 86% of the treated pseudocysts decreased in size by at least 50%.
Surgical drainage is the criterion standard against which all therapies are measured.
Internal drainage is the procedure of choice. A laparoscopic approach has been used in some cases with good results.
In most series, the mortality rate is 3%, and the complication rate is approximately 24%. The success rate is 85-90%.
Relatively recent studies have suggested that a laparoscopic approach to drainage has a high success rate and a low morbidity rate.[9, 10]
Brun A, Agarwal N, Pitchumoni CS. Fluid collections in and around the pancreas in acute pancreatitis. J Clin Gastroenterol. 2011 Aug. 45(7):614-25. [Medline].
Vege SS, Ziring B, Jain R, Moayyedi P. American Gastroenterological Association Institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology. 2015 Apr. 148(4):819-22. [Medline].
Bhasin DK, Rana SS, Sharma V, Rao C, Gupta V, Gupta R, et al. Non-surgical management of pancreatic pseudocysts associated with arterial pseudoaneurysm. Pancreatology. 2013 May-Jun. 13(3):250-3. [Medline].
Zheng M, Qin M. Endoscopic ultrasound guided transgastric stenting for the treatment of traumatic pancreatic pseudocyst. Hepatogastroenterology. 2011 Jul-Aug. 58(109):1106-9. [Medline].
Weckman L, Kylanpaa ML, Puolakkainen P, Halttunen J. Endoscopic treatment of pancreatic pseudocysts. Surg Endosc. 2006 Apr. 20(4):603-7. Epub 2006 Jan 19. [Medline].
FDA news release. FDA allows marketing of new stent for treating pseudocysts of the pancreas. December 18, 2013. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm379195.htm. Accessed: January 7, 2014.
Varadarajulu S, Bang JY, Sutton BS, Trevino JM, Christein JD, Wilcox CM. Equal Efficacy of Endoscopic and Surgical Cystogastrostomy for Pancreatic Pseudocyst Drainage in a Randomized Trial. Gastroenterology. 2013 May 31. [Medline].
Aljarabah M, Ammori BJ. Laparoscopic and endoscopic approaches for drainage of pancreatic pseudocysts: a systematic review of published series. Surg Endosc. 2007 Nov. 21(11):1936-44. [Medline].
Oida T, Mimatsu K, Kano H, Kawasaki A, Kuboi Y, Fukino N, et al. Laparoscopic Cystogastrostomy via the Posterior Approach for Pancreatic Pseudocyst Drainage. Hepatogastroenterology. 2011 Nov 14. 58(110-111):1771-1775. [Medline].
Beckingham IJ, Krige JE, Bornman PC, Terblanche J. Long term outcome of endoscopic drainage of pancreatic pseudocysts. Am J Gastroenterol. 1999 Jan. 94(1):71-4. [Medline].
Binmoeller KF, Seifert H, Walter A, Soehendra N. Transpapillary and transmural drainage of pancreatic pseudocysts. Gastrointest Endosc. 1995 Sep. 42(3):219-24. [Medline].
Criado E, De Stefano AA, Weiner TM, Jaques PF. Long term results of percutaneous catheter drainage of pancreatic pseudocysts. Surg Gynecol Obstet. 1992 Oct. 175(4):293-8. [Medline].
D'Agostino HB, vanSonnenberg E, Sanchez RB, Goodacre BW, Villaveiran RG, Lyche K. Treatment of pancreatic pseudocysts with percutaneous drainage and octreotide. Work in progress. Radiology. 1993 Jun. 187(3):685-8. [Medline].
El Hamel A, Parc R, Adda G, Bouteloup PY, Huguet C, Malafosse M. Bleeding pseudocysts and pseudoaneurysms in chronic pancreatitis. Br J Surg. 1991 Sep. 78(9):1059-63. [Medline].
Gershoni-Baruch R, Mandel H, Bar El H, Bar-Nizan N, Borochowitz Z, Dar H. Interstitial deletion (6)q13q15. Am J Med Genet. 1996 Apr 24. 62(4):345-7. [Medline].
Heider R, Meyer AA, Galanko JA, Behrns KE. Percutaneous drainage of pancreatic pseudocysts is associated with a higher failure rate than surgical treatment in unselected patients. Ann Surg. 1999 Jun. 229(6):781-7; discussion 787-9. [Medline].
Howell DA, Elton E, Parsons WG. Endoscopic management of pseudocysts of the pancreas. Gastrointest Endosc Clin N Am. 1998 Jan. 8(1):143-62. [Medline].
Lewandrowski KB, Southern JF, Pins MR, Compton CC, Warshaw AL. Cyst fluid analysis in the differential diagnosis of pancreatic cysts. A comparison of pseudocysts, serous cystadenomas, mucinous cystic neoplasms, and mucinous cystadenocarcinoma. Ann Surg. 1993 Jan. 217(1):41-7. [Medline].
Morton JM, Brown A, Galanko JA, Norton JA, Grimm IS, Behrns KE. A national comparison of surgical versus percutaneous drainage of pancreatic pseudocysts: 1997-2001. J Gastrointest Surg. 2005 Jan. 9(1):15-20; discussion 20-1. [Medline].
Nealon WH, Walser E. Surgical management of complications associated with percutaneous and/or endoscopic management of pseudocyst of the pancreas. Ann Surg. 2005 Jun. 241(6):948-57; discussion 957-60. [Medline].
Nguyen BL, Thompson JS, Edney JA, Bragg LE, Rikkers LF. Influence of the etiology of pancreatitis on the natural history of pancreatic pseudocysts. Am J Surg. 1991 Dec. 162(6):527-30; discussion 531. [Medline].
Pitchumoni CS, Agarwal N. Pancreatic pseudocysts. When and how should drainage be performed?. Gastroenterol Clin North Am. 1999 Sep. 28(3):615-39. [Medline].
Sahani DV, Kadavigere R, Saokar A, Fernandez-del Castillo C, Brugge WR, Hahn PF. Cystic pancreatic lesions: a simple imaging-based classification system for guiding management. Radiographics. 2005 Nov-Dec. 25(6):1471-84. [Medline].
Soliani P, Franzini C, Ziegler S, Del Rio P, Dell'Abate P, Piccolo D, et al. Pancreatic pseudocysts following acute pancreatitis: risk factors influencing therapeutic outcomes. JOP. 2004 Sep. 5(5):338-47. [Medline].
Vitas GJ, Sarr MG. Selected management of pancreatic pseudocysts: operative versus expectant management. Surgery. 1992 Feb. 111(2):123-30. [Medline].
Warshaw AL, Compton CC, Lewandrowski K, Cardenosa G, Mueller PR. Cystic tumors of the pancreas. New clinical, radiologic, and pathologic observations in 67 patients. Ann Surg. 1990 Oct. 212(4):432-43; discussion 444-5. [Medline].
Warshaw AL, Rutledge PL. Cystic tumors mistaken for pancreatic pseudocysts. Ann Surg. 1987 Apr. 205(4):393-8. [Medline].
Yeo CJ, Bastidas JA, Lynch-Nyhan A, Fishman EK, Zinner MJ, Cameron JL. The natural history of pancreatic pseudocysts documented by computed tomography. Surg Gynecol Obstet. 1990 May. 170(5):411-7. [Medline].